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Abstract
The relationships between cellular, structural and dynamical properties of tumors have traditionally been studied separately.
Here, we construct a quantitative, predictive theory of solid tumor growth, metabolic rate, vascularization and necrosis that
integrates the relationships between these properties. To accomplish this, we develop a comprehensive theory that
describes the interface and integration of the tumor vascular network and resource supply with the cardiovascular system of
the host. Our theory enables a quantitative understanding of how cells, tissues, and vascular networks act together across
multiple scales by building on recent theoretical advances in modeling both healthy vasculature and the detailed processes
of angiogenesis and tumor growth. The theory explicitly relates tumor vascularization and growth to metabolic rate, and
yields extensive predictions for tumor properties, including growth rates, metabolic rates, degree of necrosis, blood flow
rates and vessel sizes. Besides these quantitative predictions, we explain how growth rates depend on capillary density and
metabolic rate, and why similar tumors grow slower and occur less frequently in larger animals, shedding light on Peto’s
paradox. Various implications for potential therapeutic strategies and further research are discussed.
Citation: Herman AB, Savage VM, West GB (2011) A Quantitative Theory of Solid Tumor Growth, Metabolic Rate and Vascularization. PLoS ONE 6(9): e22973.
doi:10.1371/journal.pone.0022973
Editor: Nick Monk, University of Sheffield, United Kingdom
Received August 27, 2010; Accepted July 10, 2011; Published September 29, 2011
Copyright:  2011 Herman et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the National Science Foundation Award #PHY 0750037, NSF Grant #PHY-0946635, the Thaw Charitable Trust and the
Zwan Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: alexander.herman@ucsf.edu
Introduction
Tumor vasculature is a major target for cancer treatments.
Vascularization links together the host tissue, from which vessels
and blood are drawn, with the tumor mass and structure that is
permeated by the vascular branching that supplies tumor cells with
the necessary resources for its continued sustenance and growth.
Consequently, a complete picture of angiogenesis must unite
several disparate fields within tumor biology because it connects
diverse properties of tumor cells, host vasculature, tumor
metabolic rate and tumor growth. Understanding how these are
integrated and interconnected is crucial for developing strategies
for drug delivery and tumor treatment.
Tumors grow and are sustained by oxygen and resources
delivered via the interface of the two coupled, but essentially
autonomous, dynamical vascular networks of the host and the
tumor. It is a major theoretical challenge to understand
mechanistically the dynamics and geometry of this coupling. Part
of the difficulty is that all tumor properties depend on two mass
variables, that of the tumor and that of the host. Furthermore,
tumors typically have significant amounts of necrotic tissue so the
biologically active mass cannot simply be identified with the
physical mass.
Over the past decade, new quantitative theories for the structure
and hemodynamics of vascular networks in healthy mammalian
circulatory systems have been developed to explain allometric
scaling, with predictions that agree well with data [1,2]. These
models focus on the hierarchical, approximately self-similar
properties of the branching network and can be used to calculate
many physiological properties including blood flow rates in any
vessel, vessel sizes and densities, and network structures and
dynamics. The same framework has been successfully applied to
the respiratory system and even to plants, which differ greatly in
the physical structure and dynamics of their transport networks
[1,3]. Furthermore, it has been extended to quantitatively
understand ontogenetic growth across mammals, birds and fish
[1], and has inspired development of novel theory and collection of
novel data [4–6]. As such, it is natural to extend this paradigm to
address similar questions in tumor growth, structure and dynamics
in order to develop an analogous quantitative theory for
understanding many of their general growth and energetic
properties. Combining recent empirical data on tumors with
vascular modeling for healthy tissue provides an important method
for analyzing tumor vasculature.
In parallel with these new models for healthy vasculature,
models for tumor initiation and growth have emerged as a more
central part of cancer research [7–9]. Most similar to our
conceptual approach and goals are numerical simulations that
describe how bulk properties of tumor cells, vascular networks and
local host tissue control tumor growth [10–14]. These simulations
are performed by parameterizing systems of partial differential
equations and iterating them through time. Recent advances in
hybrid continuos-discrete models allow detailed modeling over a
wide range of spatial and temporal scales [10–14]. Within these
models, the spatial growth of tumors is simulated within their
microenvironment, and vascular networks are constructed by
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simulating the process of angiogenesis. Larger scales can be treated
by decreasing the amount of information and level of resolution of
cellular processes [13]. Such detailed modeling has produced a
rich picture of the spatial features of tumor growth.
In this paper we construct a quantitative, predictive framework
for understanding properties of tumor growth and vascularization
that can be viewed as an application of allometric theory to tumor
growth modeling. Specifically, we consider the relationship
between the architecture of vascular networks and the metabolic
and mitotic rates of individual cells. We focus on how key features
of tumor growth and metabolism depend on architectural
properties of tumor vasculature, such as vessel radii and lengths,
and how growth and metabolic rates change dynamically with
tumor size as well as with host size across species. We deliberately
simplify our model by parameterizing it in terms of average,
generic architectural properties of the tumor and host vascular
systems and the energetics of creating, maintaining and replacing
tumor cells. As such, our results are expressed in terms of relatively
few, independently measurable, operationally defined parameters
such as the average mass of a cell and the overall metabolic rate of
the host. Consequently, our model largely coarse-grains over
spatial heterogeneity, the physical interactions of the tumor cells
with each other and the environment, and effects of competition
between clonal lines of cancer cells. The benefit and power of our
approach, however, is that we obtain analytical solutions that
quantify and clarify the primary factors that affect tumor growth.
These solutions provide a baseline for characterizing and
understanding variation observed in empirical data and numerical
simulations, and facilitate comparisons with healthy vasculature
that lead to insights about optimization, altered growth rates and
treatment strategies. Furthermore, our model provides a quanti-
tative method for extrapolating parameters measured in mice and
rats to be used in numerical simulations for tumor growth in
humans. These numerical simulations, as mentioned above, can
include more details about variation in space and across cell
lineages.
We now detail our theoretical approach and data analyses.
Geometric properties of tumor vasculature are measured using
empirical data and compared against optimal predictions and
known results for healthy vasculature. Using these results, we
predict how tumor metabolic and growth rates depend on tumor
and host masses. We also derive growth equations for the various
phases of tumor development beginning with the diffusion driven
pre-angiogenesis of very small tumors to the pulsatile driven
angiogenesis of large, mature tumors. A major result of our theory,
not addressed by other models and simulations, is the derivation of
tumor metabolic rate and the recognition that the pulsatile nature
of blood flow can play an important role in the structure, dynamics
and growth of large tumors. Many specific quantitative predictions
are made that compare well with data. One major prediction of
our theory is to show how necrotic tissue necessarily arises from
vascular inefficiencies, and to explicitly calculate how necrotic
mass depends on tumor and host size.
Materials and Methods
Model
Derivation of tumor growth equation. The growth of a
tumor is controlled by nutrient supply and demand. Solid tumors
begin as avascular polyps dependent upon the diffusion of oxygen
and nutrients across the tumor surface. Further growth depends on
the recruitment and proliferation of blood vessels through
angiogenesis and is fueled by metabolic resources in the host
environment. In a process directly analogous to normal
ontogenetic growth, incoming metabolites supply the tumor with
energy and resources for creating new cells and maintaining
existing ones [15–17]. Conservation of energy requires that the
total metabolic rate of a tumor, BT , be apportioned between the
power required for maintenance and that for mitosis:
BT~NvBmzEc
dNc
dt
ð1Þ
where Nv is the number of viable cells at time t after growth
begins, Nc the total number of cells, Bm the power each cell
requires for maintenance, and Ec the energy to create a cell.
The rate of increase of the number of viable cells is the
difference between the total rate of mitosis and the rate of cell
death due to apoptosis and necrosis:
dNv
dt
~
d(Nc{Nd )
dt
ð2Þ
where Nd is the number of cells that have died by time t. Even
when the number of viable cells remains fixed (i.e., dNv=dt~0),
cells still die and are replaced by mitosis that requires tumor
resources. Moreover, apart from natural causes, cell death also
occurs due to nutrient deprivation because of inadequate or
compressed vasculature. Thus, dNd=dt has contributions from
different types of cell death, each potentially with its own
functional form. Nevertheless, we can define the inverse lifetime
of an average cell, C, by
dNd
dt
~CNv ð3Þ
Eqs. (2) and (3) closely resemble ones used in Macklin et al 2009,
but they invoke a dimensionless time by dividing by a fixed inverse
mitosis rate [10]. In contrast, we allow the inverse cell lifetime to
vary with tumor type, as determined from fits to tumor growth
data described below.
Combining Eqs. (2) and (3) we can re-express the growth
equation, Eq. (1), purely in terms of viable cells:
BT~(BmzCEc)NvzEc
dNv
dt
:BcNvzEc
dNv
dt
ð4aÞ
where Bc:BmzCEc is the average cellular metabolic power
required for maintenance and replacement. Note that the specific
metabolic rate of the tumor (i.e., per tumor cell) is proportional to
the oxygen concentration, such that BT=Nv~c0s, where s is the
oxygen concentration and c0 is a well-known conversion factor for
converting the volume flow rate of oxygen into power. Eq. (4a) can
then be expressed as
1
Nv
dNv
dt
~
1
Ec
(c0s{(Bmz
Ec
Nv
dNd
dt
)) ð4bÞ
showing explicitly how tumor growth depends on oxygen
concentration, easing the comparison with other models. In
Macklin et al 2009, for instance, the net proliferation rate (equal to
the volume rate of change) lp~s{A, where A is the rate of
apoptosis. Our equation for proliferation is similar, but is derived
mechanistically, from the energetics of the whole tumor, and thus
includes two additional terms not explicitly accounted for by
Macklin et al: Bm reflecting the oxygen used for maintaining
existing cells and Ec capturing the cost of cell creation.
Tumor Growth and Vascularization Theory
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Since the viable tumor mass, mv, is the product of the total
number of viable cells and the average mass of a cell, mc, we have
mv~Nvmc leading to
BT~(
Bc
mc
)mvz(
Ec
mc
)
dmv
dt
ð5Þ
This first-order differential equation, representing conservation of
energy, explicitly links properties of tumor cells (Bc, Ec, and mc)
with properties of the whole tumor (BT and mv). Consequently, it
provides a simple, but powerful, way to integrate important
features and results from different areas of cancer research.
Solving this equation to determine tumor growth requires
knowledge of how tumor metabolic rate, BT , depends on its
viable mass, mv, to which we now turn.
Model for tumor vascular system and the prediction of
metabolic rate. Tumor metabolic rate, BT , is proportional to
the sum of the rates of cellular fermentation and aerobic
respiration. For avascular tumors, BT depends on the diffusion
rate of nutrients and oxygen from the surrounding environment
[18]. For vascular tumors, BT is proportional to the total blood
volume flow rate to the tumor, _QT , consistent with observations
that glucose and oxygen consumption rates vary linearly with
blood flow rate [19]. The dependence of _QT on mv and host mass,
M, is determined by the structure, dynamics and interaction of the
tumor and host vasculatures. Here, we develop a complete
analytical model of tumor vascular networks applicable
throughout different phases of development by deriving the
allometric scaling of tumor rates and times with host body size
and capillary density. Although the importance of the vascular
interface between the tumor and the host has been previously
recognized, our work is a novel attempt to mechanistically model
its role in tumor growth [10–12,20].
Mounting evidence suggests that some tumor vascular networks
exhibit fractal-like properties similar to those of the circulatory
system [21–23]. To analyze tumor vasculature, we borrow from an
idealized framework that has proven successful for quantitatively
understanding the circulatory system. This framework assumes
that in healthy tissue the vasculature is space-filling, minimizes
energy loss and has invariant terminal units (capillaries) [1]. We
compare these optimal networks with measures of tumor
vasculature, while retaining the assumption of invariant capillaries.
To facilitate comparisons between healthy and tumor vascula-
ture, we introduce scaling ratios for radii and lengths of vessels
across levels, k, of the network. We treat all branches at the same
level, k, as having similar properties and assume a constant
branching ratio, n–the effective number of daughter vessels for
each mother vessel [1]. Following West et al 1997 and Gevertz et
al 2006, we model blood vessels as cylinders, similar to the Krogh
model [1,11]. The capillaries define the lowest level k~N while
the largest vessels feeding the tumor define k~0 (Fig. 1). We
introduce scale factors for the ratio of daughter to mother vessel
radii:
rkz1
rk
~n{a ð6Þ
and similarly for daughter to mother vessel lengths:
lkz1
lk
~n{b ð7Þ
The exponents, a and b, can be used as quantitative diagnostics for
comparison with healthy tissue, where theory predicts and data
support a~1=2 for large vessels and a~1=3 for small vessels (from
energy minimization) and b~1=3 for all vessels (from space filling)
[1]. Deviations from these values indicate the degree to which
optimization and space-filling are violated during tumor growth.
For healthy tissue, a and b are approximately independent of k,
indicating that the network has a fractal-like structure, as observed.
To determine if tumor vascular networks have similar geometric
structure, we observe that for vessel radii, rk
r0
~n{ka, where r0 is
the largest vessel in the hierarchy, and taking the log of both sides
and rearranging yields log rk~({a log n)kzlog r0, and similarly
for vessel lengths log lk~({b log n)kzlog l0, so plotting log rk
and log lk versus k should yield straight lines whose slopes are
{a log n and {b log n, respectively, if a and b are constant.
Figs. 2a, 2b show data from various tumors, indicating that tumor
vasculature does indeed exhibit approximately fractal behavior, in
agreement with other studies [22,24].
The metabolic rate of the tumor, determined by oxygen and
nutrient availability, depends on its capillary density, which is
controlled by the scaling factors a and b. In File S1 we derive the
relationship between the metabolic rate, tumor size and vascular
architecture:
BT~B0(M)m
b
v ð8Þ
where b~1 if 2azbƒ1, but ~1=(2azb) otherwise, and B0(M)
is a normalization factor that depends on the host mass, M. For
healthy tissue, where capillary density is controlled by large-vessel
scaling, this gives b~3=4, in agreement with data (B!M3=4) for
large mammals [25]. For tumors too small to support significant
pulsatile flow, or whose host supply vessels are likewise too small,
theory predicts a&1=3. So, if their vasculature is space-filling,
b~1 and their metabolic rate scales linearly: BT~B0(M)mv [1].
As tumor vasculature becomes increasingly inefficient and/or
attaches to host supply vessels sufficiently large to deliver pulsatile
Figure 1. Schematic of tumor growth model. (a) Vascularized
tumor supplied by blood siphoned from host vasculature. White area
represents viable tissue, while grey represents necrotic core. (b)
Schematic of vascular network composed of tubes. (c) Topological
model of tumor and host network beginning with feeding vessel (k = 0)
and terminating at the capillary level (k =N).
doi:10.1371/journal.pone.0022973.g001
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flow, BT?B0(M)mbv with b&1=(2azb)v1, ultimately decreas-
ing towards 3/4, similar to whole body scaling [2]. Indeed,
changes in this scaling exponent have been observed by Guiot et al
who determined b by matching the general form of our growth
equation to empirical data and speculated these changes were tied
to the fractal dimension of the vasculature [26]. To the extent that
a tumor network deviates from optimized space-filling architec-
ture, it will exhibit a secondary reduction in blood flow leading to
hypoxia and necrosis determined by the value of (2azb). This is
related to the development of avascular areas due to the irregular
space-filling properties observed in tumor vasculature growth [27].
During growth, tumor blood flow shows a reduction in mass-
specific blood flow rate resulting in increased necrosis [28–31],
consistent with this theory.
Model for interface of tumor and host vascular
systems. We now examine how the host vasculature
interfaces with the tumor to determine the dependence on
host mass, M, and the degree of necrosis. While previous work
has suggested relationships between host size, tumor growth
and metabolism [17,32,33], little underlying theory has been
developed, especially concerning the role of vascularization.
Many tumor growth models that consider vasculature track
how blood flows and oxygen diffuses to the tumor from a host
parent vessel. Our model goes significantly further by
considering the entire flow through and structure of both
networks, thereby showing how the blood supply from the host
changes with host body size, the size of the parent supply
vessels, and the nature of the blood flow (whether it is laminar
or pulsatile). Almost all previous investigations presume a
simple laminar flow given effectively by the classic Poisseuille
formula with time-invariant blood pressure. Our model
includes the critical role of pulsatile flow for large tumors and
considers its consequences for tumor growth and metabolism,
leading to novel and substantially different predictions than
models based purely on laminar flow.
For very small tumors, resources for metabolism are supplied by
host capillaries that have been incorporated and displaced from
the surrounding tissue. In File S1, we derive how, in this case,
capillary density and tumor metabolic rate depend on tumor and
host size, yielding
BT&½mT=MB!mT=M1=4 ð9Þ
where B is the metabolic rate of the host. Thus, the tumor
metabolic rate, BT increases linearly with total tumor mass, mT ,
but decreases with host mass as M{1=4. However, from our
network analysis for small tumors, we had B~B0(M)mv. Equating
these gives B0(M)mv&½B=MmT , mv&mT and B0(M)&
B=M!M{1=4. This predicts that, initially, little necrotic tissue
develops and that tumors begin growth approximately exponen-
tially as mT!ect=M
1=4
, where c is a constant depending on tumor
type and microenvironment. Consequently, similar tumors grow
systematically slower in larger animals due to their lower mass-
specific metabolic rate, as noted for humans [17]. More generally,
growth rates are predicted to depend on host capillary density and
metabolic rate in the tissue surrounding the tumor, in agreement
with previous models [10–12].
As tumors grow further, an anastomotic network forms from the
local host vasculature, usually at the arteriole level, eventually
either penetrating the tumor surface or becoming incorporated
into it [34]. Further growth leads to and is stimulated by
recruitment of increasingly larger supply vessels. The host tissue
from which the tumor draws blood is effectively a shell whose
thickness depends on the distance t that tumor angiogenic factors
penetrate into the surrounding host tissue. This distance depends
on production and consumption rates of angiogenic factors as they
diffuse into the local tissue environment [10–12]. Rather than
simulating this process numerically using a detailed reaction-
Figure 2. Properties of tumor vascular networks. (a) Plot of log rk
versus k. The absolute value of the slope represents the exponent a, defined
as the ratio of radii between consecutive levels: rkz1=rk~n
{a . Tumor 1:
Mammary Carcinoma 1 (red line/squares): a~0:24½{0:28;{0:21,
r2~0:96. Tumor 2: Colorectal Carcinoma (blue line/diamonds):
a~0:39½{0:44;{0:36, r2~0:98. (b) Same as (a) but for the ratio of
lengths between consecutive levels: lkz1=lk~n
{b . Tumor 1: Mammary
Carcinoma (red line/diamonds): b~0:35½{0:39;{0:24, r2~0:94. Colo-
rectal Carcinoma (blue line/circles): b~0:27½{0:40;{0:12, r2~0:67. (c)
Plot of the logarithm of flow rate versus logarithm of vessel diameter,
showing the predicted idealized cubic law (blue line y~3xzy0,
y0~{2:36½{2:44,{2:28,r2~0:71) and the best linear fit (red line
y~pxzy0, p~2:7½2:37; 3:0, y0~{1:93½{2:33;{1:53, r2~0:73). Da-
ta from [21] and [57].
doi:10.1371/journal.pone.0022973.g002
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diffusion model as others have done, we employ a classic diffusion
equation argument and take the diffusion distance, t, to vary
inversely with endothelial cell density. This density, in turn, is
determined by the surface area of host vasculature (see also
Macklin, Chaplain and Gevertz et al. [10–12]). In File S1, we
derive relationships between tumor blood flow rate, _QT , diffusion
distance t, endothelial cell density, and tumor and host size,
yielding
_QT!
tm
2=3
T
M1=4
ð10Þ
From the analysis of large tumors given above, we had
_QT!BT~B0(M)m
b
v with b&1=(2azb). Equating this with Eq.
(10) then gives
tm
2=3
T
M1=4
!B0(M)mbv ð11Þ
Furthermore, from Eq. (6) in File S1, t!M1=4, so Eq. (11) implies
B0(M)!M0 ð12Þ
That is, B0(M) is independent of M, and
mv!m
2=(3b)
T :m
c
T ð13Þ
where c~2=(3b). Consequently, when the tumor develops its own
vascular system, this predicts the non-intuitive result that the
metabolic rate of tumors of similar size no longer depends on host
size. Thus, as tumors grow, the effects of host vessel density and
shell size compensate each other, dampening the dependence of
tumor metabolic rate on the host properties. Intriguingly, this
finding, Eq. (13), also predicts that viable tumor mass increases at a
slower rate than total tumor mass, necessarily implying the
development of necrotic regions within the tumor.
In summary, when tumors are small, their metabolic rate is
limited by host capillary density, which decreases with host size as
M{1=4, whereas when tumors are large, this effect is counteracted
by the tumor’s access to more and larger host vessels. This result
embodies basic constraints arising from the interface of the host
and tumor vasculature. It has important consequences for
determining the dynamics of various properties, such as the
degree of necrosis, as we now see by examining two limiting phases
of growth.
Tumor growth dynamics. Having determined how tumor
metabolic rate scales with viable tumor mass, we discuss its
consequences for tumor growth dynamics by returning to Eq. (5).
Using BT~B0(M)m
b
v from Eq. (8), the conservation of energy
equation can be rearranged into a growth equation:
dmv
dt
~Ambv{Dmv ð14Þ
where the parameters A~B0(M)mc=Ec and D~Bc=Ec embody
generic properties of tumor cells whereas properties of the host
physiology are reflected in B0(M).
As articulated above, these coefficients and the exponent b
potentially change (in a calculable way) with time as the tumor
evolves through different phases of development. For simplicity, as
well as for illustrative purposes, we consider here the exponential
and sigmoidal phases of growth as distinct regimes where the
parameters remain fixed. The general solution to Eq. (14) is
mv
Mv
 1{b
~1{ 1{
mv(0)
Mv
 1{b" #
e{ 1{bð ÞDt ð15Þ
whereMv is the asymptotic viable mass of the tumor, as computed
below in Eq. (18), and mv(0) is the initial malignant mass. Since
mv!m
c
T , these equations can be transformed into identical
equations for the total tumor mass, mT , but with different values
of the parameters. This leads to the following important result: the
viable and total tumor masses both satisfy growth equations of the
same form as healthy tissue but with different exponents and
coefficients.
In the initial stages of tumor growth when delivery of resources
is via diffusion from nearby capillaries, the total and viable tumor
masses are linearly related (Eq. (9)). Furthermore, b&1 (see File
S1). Substituting these into Eq. (15) leads to exponential growth for
both the total and viable tumor masses:
mv&mT~mT (0)eat ð16Þ
with a~A{D~(mcB0{Bc)=Ec, determined by both cellular
and host properties.
In the early non-pulsatile regime, our model still predicts that
b&1, so from Eq. (15) exponential growth continues for the viable
mass. However, in this regime, viable and total tumor mass are
now non-linearly related, according to Eq. (13), so the total tumor
mass grows exponentially at a faster rate than the viable mass,
leading to a monotonically increasing proportion of necrotic tissue.
This can be expressed as
mv&m
2=3
T &mv(0)e
at ð17Þ
So, for small tumors that can neither support nor are supplied by
pulsatile blood flow, this predicts exponential growth for the
viable tumor mass.
Note that, if b=1, the initial growth for small times is
mv*t1=(1{b). However, if b&1, this is almost indistinguishable
from an exponential, so most tumors are expected to begin growth
approximately exponentially. As long as large host supply vessels
that support pulsatile flow do not develop, this behavior will
continue until other physical constraints become limiting or the
vascular supply is exhausted or interrupted. When angiogenesis
begins and tumor vasculature develops, resource supply does not
match demand because c&2=3, and the relative rate of increase of
mT is a factor 1=c&3=2 greater than for mv. Thus, the proportion
of viable tissue, mv=mT , decreases exponentially quickly.
In later stages we showed above that bv1; from Eq. (15) this
leads to classic sigmoidal growth with the viable mass reaching a
fixed asymptotic value given by
Mv~(A=D)
1=(1{b)~(B0(M)mc=Bc)
1=(1{b) ð18Þ
This is reached when t&(Ec=Bc)=(1{b); mv(0)~mv(ttransition) is
the corresponding mass at the time of transition from exponential
growth to the initiation of the sigmoidal phase being considered. In
the later vascular phase dominated by pulsatile flow, b&3=4 and
c&8=9, so Eq. (15) leads to sigmoidal growth with Mv!M, with
viable mass directly proportional to host mass. The asymptotic
mass of the whole tumor isMT!M9=8, suggesting proportionately
larger tumor sizes in larger animals, consistent with the limited
available data.
Tumor Growth and Vascularization Theory
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Results
Many tumor vascular properties can be derived and compared
with experiment, as well as with observed data for healthy
vasculature. For example, total vascular surface area, SA, is
predicted to scale linearly with the total number of capillaries, and
therefore linearly with the total blood volume flow rate, giving
SA!mbT , consistent with experimental observations [31,35].
Furthermore, in an optimized network, the blood volume flow
rate in a vessel at level k is predicted to follow a cubic law: _Qk!r
3
k.
Figure 2c depicts measurements from carcinomas that are
consistent with this prediction, although the greater variance
suggests tumor vasculature is less well-formed than healthy
vasculature. In addition, the total hydrodynamic resistance of
the network, Rtot, is predicted to vary inversely with the total
number of capillaries, and hence inversely with total blood flow
rate giving
Rtot!N{1cap! _Q
{1
T !m
{2=3
T ð19Þ
This equation can be rearranged to predict mTRtot!m
1=3
T (see File
S1). Data for this relationship gives an exponent of 0.36, in good
agreement with the prediction of 1/3 [36].
The predictions for the increase in size of the necrotic core and
viable mass, (Eq. (17)), are also consistent with both available data
(Fig. 3), and with numerical simulations [10]. Indeed, tumors
develop significant amounts of necrotic tissue both in their core
and in regions throughout the tumor as a result of insufficient
angiogenesis, vascular collapse and an underdeveloped lymphatic
system for the clearance of dead cells [37,38]. Finally, since the
rate constant for growth in Eq. (15) is D~Bc=Ec!M{1=4, similar
to that in normal ontogeny, typical tumor time-scales such as
doubling time, cell cycle time, and time to death are all predicted
to scale with host mass as M1=4, consistent with the limited
available data (doubling time exponent ~0:30, 0:22,0:39½ N~5,
cell cycle time exponent ~0:31, 0:23,0:39½ N~4) [39,40].
To investigate the accuracy of our growth models and the
transition between different growth regions, we fitted Eq. (15) to
tumor growth data from the literature, as shown in Fig. 4. Data are
insufficient to distinguish statistically between combined exponen-
tial and sigmoidal fits to different growth phases versus a single
sigmoidal fit to the entire dataset. Nevertheless, our fits are in good
agreement with empirical data and show the clear transition from
early exponential growth to late sigmoidal growth.
Discussion
Our model mechanistically and quantitatively connects prop-
erties of tumor cells to multiple properties of the whole tumor.
Although previous models have reproduced the sigmoidal
behavior of tumor growth, our derivation of the growth equations
is novel because it allows the extraction of observable, metabolic
quantities from our data fits that can be used to compare
metabolic properties of different tumor lines with each other and
with normal tissue [13,41]. It is notable that the confidence
intervals for parameter values estimated from our fits to sigmoidal
growth overlap with the range observed for normal growth. This
finding suggests that tumor cells retain the gross metabolic features
of normal cells, which is consistent with earlier work by Skehan
who used a large number of statistical models to conclude that the
gross properties of tumor growth are almost indistinguishable from
normal tissue growth [42]. The model also allows us to predict that
whole tumors will grow faster if their constituent cells have low Ec,
high Bc or both. This is consistent with the observation that many
aggressive tumors are inchoate and poorly differentiated, and that
their cells exhibit elevated metabolic rates. Similarly, relatively
benign tumors are expected to show higher levels of differentiation
and lower mass-specific rates of energy use. If Bc=Ec is not
significantly different from its value for healthy cells, this suggests
that at late stages such tumors grow at relative rates comparable to
that of healthy organs during ontogeny.
Our framework makes several predictions that relate to the
diagnosis and treatment of solid tumors. First, it clearly
distinguishes between different growth regimes: 1. Pre-angiogen-
esis/diffusion regime, 2. Early angiogenesis/smooth, laminar non-
pulsatile blood flow regime, and 3. Late angiogenesis/pulsatile
flow. In regimes 1 and 2, we predict that growth rates are
systematically much faster in smaller mammals (Eq. (9)), whereas
in regime 3, growth rates are independent of host body size (Eq.
(12)). This suggests that early detection of tumors is even more
critical than currently recognized because that is the regime during
which tumors in humans exhibit proportionately slower growth
rates than in smaller mammals. Moreover, these results also
suggest that different treatments should be developed for, and
tailored to, these different growth regimes.
Our results have potentially important consequences for scaling
up experimental findings from mice to humans. One testable
prediction of our model, confirmed by preliminary evidence, is
that human to mouse tumor xenografts will grow at a rate similar
to endogenous mouse tumors, as opposed to human tumors
[39,40]. Differing predictions for different growth regimes derived
above suggest that treatment and drug dosages obtained from
mice studies must be properly scaled up and applied to humans
only after careful consideration of both the mouse’s and patient’s
tumor growth regimes.
Resolving questions about cancer incidence rates in different
species, and thus Peto’s paradox, may also be possible by
considering scaling consequences as a function of body mass and
metabolic rate [43–45]. Tumors must develop a number of specific
mutations along a single cell lineage to become malignant,
probably in a specific order [7,46]. Although the total number
of cells in the body increases almost linearly with body size, the
number of cell-generations increases only logarithmically with
body size [47]. If most cancer-causing events occur during cell
division, the whole-body probability of developing a lineage of
Figure 3. Scaling of tumor viable mass, mv, as a function of the
total tumor mass, mT . Theory predicts that mv!m
2=(3b)
T :m
c
T . In this
case, logmv~c logmTzlogmv(0); c~0:78½0:76; 0:78, r2~0:99, so that
for these tumors b&0:85, implying a high blood-flow/metabolic rate.
However, since these data are drawn from multiple tumors, it
represents an estimate. Data from [58].
doi:10.1371/journal.pone.0022973.g003
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mutations is then proportional to the product of the number of
generations of cell division and the probability of mutation per cell
generation. The power density driving biochemical reactions
within a cell scales as Bc!M{1=4, and if these biochemical
reaction rates drive mutation rates, for instance through the
production of reactive oxygen species, then overall cancer
incidence rates would scale as M{1=4 logM, which becomes
dominated by the M{1=4 term after the first couple orders of
magnitude [48]. Indeed, this leads to the sensible prediction that
cancer incidence rates scale inversely to maximum lifespan, which
scales approximately as body size to the quarter power (M1=4)
[49]. Thus, smaller mammals are systematically expected to have a
greater incidence rate of a given tumor than larger mammals.
In addition, our theory sheds light on how a large number of
rates and time-scales considered in numerical models, such as
tumor angiogenic factor production, cell-cycle time, rate of
apoptosis and necrosis, and oxygen concentration, should be
adjusted with tumor and host size. For some of these parameters,
such as tumor angiogenic factor production rate _T , we can
immediately predict how they scale with host and tumor size: early
on for small tumors, as _T!mT=M1=4 whereas, later for large
tumors, as _T!M0mcT .
Although we made simplifying assumptions to reflect existing
quantitative knowledge of tumor kinetics, the framework can be
straightforwardly extended to capture more complex details of
tumor growth. For example, tumor metabolic scaling will vary
Figure 4. Fits of the growth equation to empirical data for tumor growth. Exponential, from Eq. (16), and sigmoidal, from Eq. (15), regimes
of the growth equation, where mT is the tumor mass at time t, m(0) is the initial mass,MT is the asymptotic mass, a~A{D~ mcB0{Bcð Þ=Ec is the
rate of exponential growth, c is the viable mass scaling exponent, and D~Bc=Ec is a characteristic time constant for tumor cells that is given by the
ratio of the metabolic rate of a tumor cell to the energy to create a tumor cell. Fits to several types of tumors implanted in mice and rats yield the
parameter values with corresponding confidence intervals of: (a) EMT6 exponential: m(0)~0:036g, ac~0:11d
{1 ; EMT6 sigmoidal: MT~1:38g,
D~0:14d{1 . (b) KHJJ exponential: m(0)~0:04g, ac~0:1d
{1 ; KHJJ sigmoidal: MT~1:5g, D~0:29d
{1 . (c) NCTC2472 exponential: m(0)~0:25g,
a
c~0:1d
{1; NCTC2472 sigmoidal: MT~13g, D~0:05d
{1 . (d) C3H exponential: m(0)~0:20g, ac~0:036d
{1 ; C3H sigmoidal: MT~8g; D~0:03d
{1.
Using c~0:78 based on the fit from Fig. 3, we compute that for the tumor types in panels (a)–(d), a~0:09d{1 , 0:09d{1 , 0:03d{1 , and 0:1d{1
respectively, which is remarkably consistent given the amount of error in the data. Data from [40].
doi:10.1371/journal.pone.0022973.g004
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depending on how the architecture of specific tumor vascular
networks deviate from optimality. Therefore, no single power law
will exactly describe the host size dependence across all tumors.
Our model does not explicitly treat spatial features of tumor
growth. Moreover, many parameters that are explicit in other
models are implicit components of our model, including _T , blood-
tissue oxygen transfer rates, the oxygen diffusion coefficient and
the oxygen concentration threshold for quiescence and necrosis
[10]. Currently, the cellular energetic parameters Bc, Ec and
B0(M), and the scaling exponents, subsume the average effects of
spatial processes such as cell motility. More detailed models would
allow the decomposition of these parameters into underlying
microscopic processes constraining tumor growth that are
considered explicitly in numerical approaches. For example, a
reaction-diffusion model for angiogenic factor gradients and host
vessel recruitment, or a lattice-model of cellular motility and cell-
cell adhesion, would allow for more fine-grained simulations of
spatially resolved tumor vasculature and growth co-development
[10,12–14,50]. Cell motility could be expressed in terms of the
energy used by cells to move and thus be connected to the cell’s
energy budget. Because of energetic constraints, the cell velocity or
number of motile cells in a spatial-version of our model would thus
be constrained by the blood supply and hence tumor and host size.
Furthermore, many models of tumor growth include three
distinct layers: proliferating, quiescent and necrotic [10,13,14,50].
In our model, we combine the proliferating and quiescent layers.
Modeling proliferating and quiescent cells as separate layers with a
transition region would involve the expansion of our theory to
capture the effect of oxygen concentration on cell state, as
influenced by tumor and host size. Because oxygen concentration
in the tumor is the main determinant of the balance between the
number of proliferating and quiescent cells, we expect the number
of proliferative cells to decline across host species with increasing
host mass as M{1=4 during the early growth stage and then scale
only with tumor size as the tumor grows larger. Hence, studies in
small mammals (e.g., mice) of therapies such as chemotherapy and
radiation, which are targeted at actively dividing cells in relatively
small tumors, may result in an effect larger than what should be
expected in humans.
We assumed that the inverse cellular lifetime, C, is independent
of time or tumor size, consistent with the constant mitotic rate
assumed in other models such as Macklin et al 2009. A more
detailed model could account for dependencies on viable mass due
to factors such as heterogeneous spatial distribution of blood flow
and interstitial fluid pressure [51]. As long as these effects are
small, our theory gives a leading-order description of tumor
necrosis, although it cannot predict its spatial distribution.
Additionally, while the cellular energetics parameters Bc and Ec
may vary during tumor growth due to a changing environment
and the emergence of new cell phenotypes, we have suppressed a
sum over cell types and clonal populations and have made the
simplification that tumors are composed of average cells.
Extending our model to include growth parameters that evolve
with emerging clonal populations may prove useful in under-
standing how drug dosages in chemotherapy could be dynamically
adjusted [52]. Accurate in vivo measurements of tumor metabolic
and mitotic rates, increasingly feasible with advances in imaging
technology, would also allow us to provide more precise
predictions for the behavior of growing tumors, and may also be
useful in describing effects of the approach of normalizing and
then destroying tumor vasculature [53]. More exact measurements
of tumor growth rates would allow for tighter bounds on the values
of Bc and Ec derived from growth fits, and conversely, more
detailed and accurate measurements of tumor cellular metabolic
properties would allow for the quantitative prediction of tumor
growth.
To summarize: we have presented a general quantitative
framework that captures many of the essential features of tumor
vascularization and growth, and how these are influenced by the
host organism. We derived predictions for many rates. times and
sizes of both solid tumors and their vascular networks as they grow
and interconnect. In addition, we predict how many of these
properties depend on host body size, thus laying groundwork for
resolving the long-debated issue of how cancer incidence rates
scale from mice to humans [54]. Similarly, these results may help
us understand how to scale results from experiments on model
organisms up to humans, possibly through scaled parameteriza-
tions of numerical models, and also how drug dosages are affected
by tumor metabolic rate, vascularization and growth stage [55,56].
By focusing on metabolic rate, our integrative model allows for
quantitative comparisons between tissue and cellular level growth
for tumors, as well as comparisons of these quantities among
different types of normal tissue and solid tumors.
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